Feline Upper Respiratory Infection: Chlamydia felis and Bordetella bronchiseptica Management

1. Introduction

Feline upper respiratory infection (URI) is a syndrome of multifactorial etiology involving both viral and bacterial agents. While viruses such as feline herpesvirus-1 (FHV-1), feline calicivirus (FCV), and feline reovirus are primary incitants, bacterial pathogens including Chlamydia felis and Bordetella bronchiseptica are recognized as significant primary or secondary contributors. Accurate differentiation between viral and bacterial causes is essential for targeted antimicrobial stewardship and improved clinical outcomes. This article provides an exhaustive review of the biology, pathogenesis, diagnostic approaches, and management strategies for C. felis and B. bronchiseptica in feline URI, with emphasis on PCR-based panel testing and the use of doxycycline as the cornerstone of therapy.

2. Aetiology and Epidemiology

2.1 Chlamydia felis

C. felis is a Gram-negative, obligate intracellular bacterium belonging to the family Chlamydiaceae. It possesses a biphasic developmental cycle alternating between infectious elementary bodies (EBs) and metabolically active reticulate bodies (RBs) within host epithelial cells. The organism exhibits tropism for conjunctival, respiratory, and genital mucosal epithelium. In cats, C. felis is a leading cause of conjunctivitis, often presenting with chemosis, serous to mucopurulent ocular discharge, and blepharospasm [1, 2]. Respiratory signs such as sneezing and nasal discharge are less prominent but can occur. The pathogen is shed in ocular and nasal secretions, with transmission via direct contact or fomites. Prevalence estimates in shelter populations range from 5% to 30%, with higher rates in multi-cat environments [3, 4].

2.2 Bordetella bronchiseptica

B. bronchiseptica is a Gram-negative, aerobic coccobacillus of the family Alcaligenaceae. It is a respiratory pathogen of multiple mammalian species, including cats, dogs, pigs, and rabbits. In felines, B. bronchiseptica primarily causes tracheobronchitis with a dry, hacking cough, but can also contribute to more severe pneumonia in kittens or immunocompromised adults [5, 6]. The organism expresses several virulence factors, including filamentous hemagglutinin (FHA), adenylate cyclase toxin, and a type III secretion system (T3SS) that facilitates adherence to and invasion of respiratory epithelial cells [7]. B. bronchiseptica is zoonotic, capable of causing respiratory disease in immunocompromised humans, which necessitates careful history taking in clinical settings [8].

3. Pathogenesis and Host Interaction

3.1 Attachment and Cellular Invasion

Both pathogens adhere to ciliated respiratory and conjunctival epithelial cells. C. felis EBs bind via heparan sulfate-like glycosaminoglycans and use a type III secretion apparatus to inject effector proteins that promote internalization. Once inside, the inclusion membrane isolates the RBs from host cytoplasmic defenses [9]. B. bronchiseptica employs FHA and fimbriae for adherence, then uses its T3SS to inject BopN and other effectors that modulate host cell signaling, inhibit apoptosis, and suppress ciliary function [10].

3.2 Immune Evasion

C. felis evades host immunity by modulating interferon-gamma responses and downregulating major histocompatibility complex (MHC) class II expression on infected cells [11]. B. bronchiseptica produces an adenylate cyclase toxin that impairs phagocyte function and contributes to persistent colonization [12]. Both organisms can establish subclinical carrier states, with intermittent shedding upon stress [13].

4. Clinical Presentation and Differential Diagnosis

Feline URI caused by C. felis and B. bronchiseptica shares overlapping clinical signs with viral pathogens FHV-1 and FCV. Key differentiating features are summarized in Table 1.

Table 1. Clinical differentiation of common feline URI pathogens

Viral etiologies are more likely to be associated with oral ulceration (FCV) and corneal involvement (FHV-1). A persistent cough is highly suggestive of B. bronchiseptica [6, 14].

5. Diagnostic Approaches

5.1 Sample Collection

Optimal samples include conjunctival swabs (for C. felis) and deep nasal or oropharyngeal swabs (for B. bronchiseptica). Flocked swabs with transport medium are preferred to maintain bacterial viability for culture and to preserve nucleic acids for PCR [15].

5.2 Culture and Isolation

C. felis requires cell culture (McCoy or HeLa cells) with incubation for 48–72 hours followed by immunofluorescence staining. B. bronchiseptica grows on blood agar or MacConkey agar within 24–48 hours, producing small, convex, beta-hemolytic colonies [16]. Culture is useful for antimicrobial susceptibility testing but is time-consuming and less sensitive than molecular methods [17].

5.3 Molecular Diagnostics: Multiplex PCR Panels

Commercially available multiplex PCR panels simultaneously detect FHV-1, FCV, C. felis, B. bronchiseptica, and Mycoplasma felis from a single swab. These assays amplify conserved genetic targets such as the ompA gene of C. felis and the fla gene of B. bronchiseptica [18, 19]. Real-time quantitative PCR (qPCR) provides cycle threshold (Ct) values that can differentiate high-level acute infection from low-level carrier shedding. A Ct value less than 30 is generally associated with active clinical disease [20].

The sensitivity of qPCR for C. felis approaches 98% compared to culture, and for B. bronchiseptica it exceeds 95% [21, 22]. False positives due to non-viable organisms are rare but possible; clinical correlation is essential.

5.4 Serology

Serological tests (indirect immunofluorescence, ELISA) for anti-chlamydial antibodies are available but not recommended for acute diagnosis due to a 2–3 week lag in seroconversion and cross-reactivity with other chlamydial species [23]. Acute and convalescent titers can support retrospective diagnosis.

5.5 Point-of-Care Antigen Tests

Rapid immunochromatographic tests for C. felis antigen exist but exhibit lower sensitivity than PCR (approximately 70–80%) and are not available for B. bronchiseptica in the feline context [24]. PCR remains the standard.

6. Antimicrobial Therapy

6.1 Doxycycline: First-Line Agent

Doxycycline is the antimicrobial of choice for both C. felis and B. bronchiseptica infections. It acts by binding to the 30S ribosomal subunit, inhibiting protein synthesis. The drug exhibits high oral bioavailability in cats, although esophageal stricture is a known risk; administration with a fluid bolus or use of compounded suspensions mitigates this [25, 26].

Standard dosing: 5 mg/kg orally every 12 hours, or 10 mg/kg every 24 hours, for a minimum of 14 days. For C. felis, a longer course of 4 weeks is recommended to eliminate the carrier state [27]. For B. bronchiseptica, 10–14 days is usually sufficient, though persistent cases may require extension [28].

Table 2. Antimicrobial options for C. felis and B. bronchiseptica

6.2 Antimicrobial Stewardship

Routine use of antibiotics for all feline URI is discouraged. PCR panel results should guide therapy. In shelter settings, empirical doxycycline is justified when C. felis is endemic, but escalation to broader agents should be avoided [31]. B. bronchiseptica resistance to tetracyclines is rare but documented; susceptibility testing is prudent when treatment fails [32].

7. Supportive Care and Management

Supportive therapy includes humidification, nutritional support (appetite stimulants or assisted feeding if oral ulceration present), and ocular lubrication. Topical tetracycline ophthalmic ointments are not systemically absorbed but can reduce ocular shedding of C. felis [33]. Nebulization with saline and bronchodilators may benefit cats with severe B. bronchiseptica tracheobronchitis [34].

8. Prevention and Control

8.1 Vaccination

Modified-live intranasal vaccines are available for B. bronchiseptica in cats. They provide partial protection and are recommended in high-risk shelters and catteries [35]. No commercially licensed C. felis vaccine exists in many regions; inactivated bacterins are used in some European countries but efficacy is variable [36].

8.2 Environmental Management

Both pathogens are susceptible to common disinfectants (quaternary ammonium compounds, bleach 1:32 dilution). C. felis EBs are stable in the environment for several days; B. bronchiseptica survives for up to 2 weeks in moist conditions. Frequent disinfection of food bowls, bedding, and housing surfaces is critical [37].

9. Diagnostic and Treatment Algorithm

The following Mermaid diagram outlines a recommended diagnostic workflow for feline URI with suspected bacterial involvement.

flowchart TD
    A["Feline URI signs: sneezing, conjunctivitis, cough"], > B["Collect conjunctival + oropharyngeal swab"]
    B, > C["Submit for multiplex PCR panel:\nFHV-1, FCV, C. felis, B. bronchiseptica, M. felis"]
    C, > D{"PCR results"}
    D, "C. felis positive", > E["Doxycycline 5 mg/kg PO q12h x 4 weeks"]
    D, "B. bronchiseptica positive", > F["Doxycycline 10 mg/kg PO q24h x 14 days"]
    D, "Viral positive only (FHV-1, FCV)", > G["Supportive care, no antibiotics"]
    D, "All negative", > H["Re-evaluate sample quality; consider culture for Mycoplasma"]
    E, > I["Recheck PCR at 4 weeks if clinical signs persist"]
    F, > J["If cough persists >14 days: susceptibility testing"]
    I, > K["If Ct < 30 continue doxycycline; consider azithromycin"]
    J, > K
    K, > L["Resolved: discontinue"]

10. Prognosis

With appropriate therapy, clinical signs attributable to C. felis and B. bronchiseptica typically resolve within 1–2 weeks. Chronic carrier states may persist despite treatment, particularly for C. felis. Recurrence is uncommon unless reinfection occurs in multi-cat environments [38].

11. Zoonotic Considerations

B. bronchiseptica can cause respiratory disease in immunocompromised humans, including those with HIV/AIDS, cystic fibrosis, or organ transplants [39]. Veterinarians should advise owners with immunosuppression to practice hand hygiene and restrict close contact with affected cats. C. felis has been associated with ocular infections in humans handling infected cats, though reported cases are rare [40].

12. Conclusion

C. felis and B. bronchiseptica are important bacterial causes of feline URI that require laboratory confirmation through multiplex PCR panel testing to differentiate from more common viral etiologies. Doxycycline remains the antimicrobial of choice, with extended courses necessary for C. felis clearance. Early molecular diagnosis, targeted therapy, and appropriate biosecurity measures reduce morbidity and limit transmission in shelter and multi-cat settings.

References

[1] Sykes JE. Feline chlamydiosis. Clin Tech Small Anim Pract. 2005;20(2):130-134.

[2] TerWee J, et al. Characterization of the systemic disease and ocular phenotype of a feline Chlamydia felis infection model. Vet Microbiol. 2004;101(1-2):93-102.

[3] Di Francesco A, et al. Prevalence of Chlamydia felis in stray cats in Italy. J Feline Med Surg. 2012;14(8):563-566.

[4] Bannasch MJ, Foley JE. Epidemiologic evaluation of multiple respiratory pathogens in cats in animal shelters. J Feline Med Surg. 2005;7(2):109-119.

[5] Welsh RD. Bordetella bronchiseptica infections in cats. J Am Anim Hosp Assoc. 1996;32(2):150-156.

[6] Helps CR, et al. Factors associated with upper respiratory tract disease caused by feline herpesvirus, feline calicivirus, Chlamydophila felis and Bordetella bronchiseptica in cats: a prospective study. Vet Rec. 2005;156(21):654-660.

[7] Cotter PA, Miller JF. Bordetella. In: Principles of Bacterial Pathogenesis. Academic Press; 2001:519-546.

[8] Giselbrecht J, et al. Zoonotic transmission of Bordetella bronchiseptica from a domestic cat to a human. J Clin Microbiol. 2018;56(10):e01005-18.

[9] Rank RG, Whittum-Hudson JA. Immunology of chlamydial infection. In: Chlamydia: Intracellular Pathogens. ASM Press; 2015:243-274.

[10] Yuk MH, et al. The BvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica. Mol Microbiol. 1998;28(5):945-959.

[11] Pospischil A, et al. Abortions in cynomolgus monkeys caused by Chlamydia felis. Vet Pathol. 2004;41(2):155-161.

[12] Harvill ET, et al. Virulence functions and host interactions of Bordetella bronchiseptica. Microbes Infect. 2000;2(8):919-925.

[13] Wardley RC, et al. Feline chlamydial infection. Vet Annu. 1992;32:180-186.

[14] Sykes JE, et al. Prevalence of feline upper respiratory tract pathogens in shelter cats. J Feline Med Surg. 2001;3(4):213-219.

[15] Quigley BL, et al. Comparison of flocked and rayon swabs for detection of feline respiratory viruses by PCR. J Vet Diagn Invest. 2016;28(6):692-695.

[16] Greene CE, et al. Bacterial respiratory infections. In: Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:891-906.

[17] Hartmann AD, et al. Detection of Chlamydophila felis in cats with conjunctivitis by PCR and cell culture. Vet Microbiol. 2005;109(3-4):233-237.

[18] Helps CR, et al. Use of real-time PCR for the detection of feline herpesvirus, feline calicivirus and Chlamydophila felis in cats. Vet Rec. 2003;152(19):591-594.

[19] Maggs DJ, et al. Evaluation of a multiplex PCR for detection of feline respiratory pathogens. J Vet Intern Med. 2007;21(3):527-532.

[20] Sandmeyer LS, et al. Quantitative real-time PCR for Chlamydia felis: correlation with clinical severity. Vet Ophthalmol. 2010;13(1):21-27.

[21] Schulz BS, et al. Detection of feline respiratory pathogens by real-time PCR. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2011;39(6):399-406.

[22] Muisier JN, et al. Comparison of culture and PCR for Bordetella bronchiseptica detection in cats. J Feline Med Surg. 2009;11(5):405-409.

[23] Wills JM, et al. Serological diagnosis of feline chlamydial infection. Vet Rec. 1988;122(26):625-627.

[24] O'Rourke M, et al. Evaluation of a point-of-care antigen test for Chlamydia felis in cats. J Feline Med Surg. 2015;17(6):503-508.

[25] Papich MG. Tetracycline antibiotics. In: Saunders Handbook of Veterinary Drugs. 4th ed. Elsevier; 2016:721-725.

[26] German AJ, et al. Esophageal stricture in cats associated with doxycycline administration. J Feline Med Surg. 2005;7(2):113-117.

[27] Sparkes AH, et al. Doxycycline therapy for feline chlamydial infection. Vet Rec. 1999;145(13):374-376.

[28] Egberink H, et al. Bordetella bronchiseptica infection in cats. J Feline Med Surg. 2009;11(7):582-585.

[29] Gerriets W, et al. Azithromycin therapy for feline chlamydiosis. Vet Dermatol. 2006;17(6):419-424.

[30] Foley JE, et al. Antimicrobial susceptibility of Bordetella bronchiseptica isolates from cats. J Vet Intern Med. 2002;16(4):468-472.

[31] Dinnage JD, et al. The effect of empirical antibiotic therapy on antimicrobial resistance in feline respiratory isolates. J Feline Med Surg. 2008;10(6):555-562.

[32] Register KB, et al. Antimicrobial susceptibility of Bordetella bronchiseptica isolates from swine and companion animals. J Clin Microbiol. 2012;50(6):2053-2057.

[33] Wills JM, et al. Topical tetracycline therapy for feline chlamydial conjunctivitis. Vet Rec. 1987;121(25-26):584-585.

[34] Rozanski EA, et al. Nebulization therapy in cats with lower airway disease. J Feline Med Surg. 2003;5(4):225-230.

[35] Lappin MR, et al. Efficacy of an intranasal Bordetella bronchiseptica vaccine in cats. J Am Vet Med Assoc. 1995;207(10):1312-1315.

[36] Ponzio NM, et al. Vaccination against Chlamydia felis in cats: a review. Vet J. 2011;189(1):15-20.

[37] Sykes JE. Disinfection and infection control in feline shelters. J Feline Med Surg. 2010;12(9):691-699.

[38] Helps CR, et al. Persistence of Chlamydia felis infection after doxycycline treatment. Vet Rec. 2008;163(4):118-119.

[39] Mattoo S, et al. Human infections associated with Bordetella bronchiseptica. Clin Microbiol Rev. 2000;13(3):510-517.

[40] Hartley JC, et al. Chlamydia felis infection in humans. Lancet. 2001;357(9256):617-618.

[41] Bandi C, et al. Molecular characterization of Chlamydia felis in Italian cats. Vet Microbiol. 2006;117(2-4):247-252.

[42] Gaskell RM, et al. Feline respiratory disease complex: viral and bacterial interactions. Vet Rec. 1984;114(6):151-153.

[43] Pedersen NC, et al. A review of feline infectious peritonitis virus and feline coronaviruses. Vet Pathol. 1976;13(1):1-14.

[44] Binns SH, et al. Prevalence of feline upper respiratory tract pathogens in rescue shelters. Vet Rec. 1999;145(18):519-522.

[45] Cave TA, et al. Treatment of feline chlamydial conjunctivitis with oral doxycycline. Vet Rec. 2002;151(2):59-61.

[46] Weigler BJ, et al. Seroprevalence of Chlamydia felis in cats with respiratory disease. J Am Vet Med Assoc. 1994;204(7):1109-1112.

[47] Veir JK, et al. Prevalence of selected infectious organisms in cats with upper respiratory disease. J Am Vet Med Assoc. 2004;224(7):1102-1107.

[48] Sykes JE, et al. Feline upper respiratory tract disease: a case-control study. J Feline Med Surg. 2001;3(4):203-212.

[49] Lutz H, et al. Detection of Chlamydia felis by PCR in cats with conjunctivitis. J Clin Microbiol. 1996;34(10):2465-2467.

[50] Studdert MJ, et al. A review of feline respiratory disease complex. Aust Vet J. 1995;72(12):462-466.